Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Кардиоваскулярная безопасность как критерий выбора нестероидных противовоспалительных препаратов в лечении болевых синдромов
Широков В.А. Кардиоваскулярная безопасность как критерий выбора нестероидных противовоспалительных препаратов в лечении болевых синдромов. Consilium Medicum. 2015; 17 (9): 104–107. DOI: 10.26442/2075-1753_2015.9.103-107
________________________________________________
Shirokov V.A. Cardiovascular security as selection criteria for nonsteroidal anti-inflammatory drugs in the treatment of pain syndromes. Consilium Medicum. 2015; 17 (9): 104–107. DOI: 10.26442/2075-1753_2015.9.103-107
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Проблема использования нестероидных противовоспалительных препаратов (НПВП) связана с развитием осложнений со стороны сердечно-сосудистой системы и желудочно-кишечного тракта. В обзоре представлены результаты клинико-эпидемиологических исследований эффективности и безопасности напроксена, демонстрирующие наиболее низкий среди всех НПВП риск развития осложнений со стороны сердечно-сосудистой системы.
Ключевые слова: болевые синдромы, нестероидные противовоспалительные препараты, кардиоваскулярная безопасность.
Ключевые слова: болевые синдромы, нестероидные противовоспалительные препараты, кардиоваскулярная безопасность.
________________________________________________
The problem of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with the development of complications of the cardiovascular system and gastrointestinal tract. The review presents the results of clinical and epidemiological studies on the efficacy and safety of naproxen, demonstrating the lowest among all NSAIDs the risk of developing complications of the cardiovascular system.
Key words: pain syndromes, nonsteroidal anti-inflammatory drugs, cardiovascular safety.
Key words: pain syndromes, nonsteroidal anti-inflammatory drugs, cardiovascular safety.
Полный текст
Список литературы
1. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике (клинические рекомендации). Совр. ревматология. 2015; 1: 361. / Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike (klinicheskie rekomendatsii). Sovr. revmatologiia. 2015; 1: 361. [in Russian]
2. Насонов Е.Л. Вступительное слово. РМЖ. 2015; 7: 361. / Nasonov E.L. Vstupitel'noe slovo. RMZh. 2015; 7: 361. [in Russian]
3. Каратеев А.Е. Модификация традиционных НПВП как метод повышения их безопасности и удобства применения. РМЖ. 2015: 7: 392–8. / Karateev A.E. Modifikatsiia traditsionnykh NPVP kak metod povysheniia ikh bezopasnosti i udobstva primeneniia. RMZh. 2015: 7: 392–8. [in Russian]
4. Широков В.А. Выбор нестероидных противовоспалительных препаратов в лечении болевого синдрома с позиции кардиоваскулярной безопасности. РМЖ. 2015; 12: 716–9. / Shirokov V.A. Vybor nesteroidnykh protivovospalitel'nykh preparatov v lechenii bolevogo sindroma s pozitsii kardiovaskuliarnoi bezopasnosti. RMZh. 2015; 12: 716–9. [in Russian]
5. Loo C, Tan H, Teh H, Raymond A. Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J 2007; 48 (9): 834–9.
6. Strand V, Simon LS, Dougados M et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol 2011; 38 (12): 2625–34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1.
7. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8.
8. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–29.
9. Kimmel SE, Berlin JA, Reilly M et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157–64.
10. Bresalier RS, Sandier RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102.
11. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009. / Karateev A.E., Iakhno N.N., Lazebnik L.B. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. M.: IMA-PRESS, 2009. [in Russian]
12. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiol 2000; 11: 382–7.
13. Garcia Rodriguez L, Varas-Lorenzo C, Maguire A et al. Non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in general population. Circulation 2004; 109: 3000–6.
14. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular eventswith naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105–11.
15. MacDonald T, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573–4.
16. Ray WA, Stein CM, Hall K et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118–23.
17. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of nonsteroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; Jan 11: 342: c7086. Doi: 10.1136/bmj.c7086.
18. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006; 296: 1633–44.
19. Wong D, Wang М, Cheng Y, Fitzgerald GA. Cardiovascular hazard and non-stertoidal anti-inflammatory drugs. Curr Opin Pharmacol 2005; 5: 204–10.
20. Chan CC, Reid CM, Aw TJ et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27 (12): 2332–41. Doi:10.1097/HJH.0b013e3283310dc9
21. Solomon D, Glynn R, Levin R, Avarn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099–4.
22. Vascular and upper gastrointestinal effects of non-steroidal anti-infl ammatory drugs: meta-analyses of individual participant data from randomised trials Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Lancet 2013; 382: 769–79.
23. Sharon Hertz. Cайт FDA.
24. Singh G, Graham D, Wang H et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some nonselective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65 (Suppl. II): 61 (OP0024 abst.).
25. Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studie. Pharmacoepidemiol Drug Saf 2013; 22: 559–70. Doi: 10.1002/pds Published online 25 April 2013 in Wiley OnlineLibrary
26. Инструкция по медицинскому применению препарата Налгезин. / Instruktsiia po meditsinskomu primeneniiu preparata Nalgezin. [in Russian]
27. Инструкция по медицинскому применению препарата Налгезин форте. / Instruktsiia po meditsinskomu primeneniiu preparata Nalgezin forte. [in Russian]
2. Насонов Е.Л. Вступительное слово. РМЖ. 2015; 7: 361. / Nasonov E.L. Vstupitel'noe slovo. RMZh. 2015; 7: 361. [in Russian]
3. Каратеев А.Е. Модификация традиционных НПВП как метод повышения их безопасности и удобства применения. РМЖ. 2015: 7: 392–8. / Karateev A.E. Modifikatsiia traditsionnykh NPVP kak metod povysheniia ikh bezopasnosti i udobstva primeneniia. RMZh. 2015: 7: 392–8. [in Russian]
4. Широков В.А. Выбор нестероидных противовоспалительных препаратов в лечении болевого синдрома с позиции кардиоваскулярной безопасности. РМЖ. 2015; 12: 716–9. / Shirokov V.A. Vybor nesteroidnykh protivovospalitel'nykh preparatov v lechenii bolevogo sindroma s pozitsii kardiovaskuliarnoi bezopasnosti. RMZh. 2015; 12: 716–9. [in Russian]
5. Loo C, Tan H, Teh H, Raymond A. Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J 2007; 48 (9): 834–9.
6. Strand V, Simon LS, Dougados M et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol 2011; 38 (12): 2625–34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1.
7. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8.
8. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–29.
9. Kimmel SE, Berlin JA, Reilly M et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157–64.
10. Bresalier RS, Sandier RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102.
11. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009. / Karateev A.E., Iakhno N.N., Lazebnik L.B. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. M.: IMA-PRESS, 2009. [in Russian]
12. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiol 2000; 11: 382–7.
13. Garcia Rodriguez L, Varas-Lorenzo C, Maguire A et al. Non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in general population. Circulation 2004; 109: 3000–6.
14. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular eventswith naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105–11.
15. MacDonald T, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573–4.
16. Ray WA, Stein CM, Hall K et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118–23.
17. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of nonsteroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; Jan 11: 342: c7086. Doi: 10.1136/bmj.c7086.
18. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006; 296: 1633–44.
19. Wong D, Wang М, Cheng Y, Fitzgerald GA. Cardiovascular hazard and non-stertoidal anti-inflammatory drugs. Curr Opin Pharmacol 2005; 5: 204–10.
20. Chan CC, Reid CM, Aw TJ et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27 (12): 2332–41. Doi:10.1097/HJH.0b013e3283310dc9
21. Solomon D, Glynn R, Levin R, Avarn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099–4.
22. Vascular and upper gastrointestinal effects of non-steroidal anti-infl ammatory drugs: meta-analyses of individual participant data from randomised trials Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Lancet 2013; 382: 769–79.
23. Sharon Hertz. Cайт FDA.
24. Singh G, Graham D, Wang H et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some nonselective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65 (Suppl. II): 61 (OP0024 abst.).
25. Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studie. Pharmacoepidemiol Drug Saf 2013; 22: 559–70. Doi: 10.1002/pds Published online 25 April 2013 in Wiley OnlineLibrary
26. Инструкция по медицинскому применению препарата Налгезин. / Instruktsiia po meditsinskomu primeneniiu preparata Nalgezin. [in Russian]
27. Инструкция по медицинскому применению препарата Налгезин форте. / Instruktsiia po meditsinskomu primeneniiu preparata Nalgezin forte. [in Russian]
________________________________________________
1. Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike (klinicheskie rekomendatsii). Sovr. revmatologiia. 2015; 1: 361. [in Russian]
2. Nasonov E.L. Vstupitel'noe slovo. RMZh. 2015; 7: 361. [in Russian]
3. Karateev A.E. Modifikatsiia traditsionnykh NPVP kak metod povysheniia ikh bezopasnosti i udobstva primeneniia. RMZh. 2015: 7: 392–8. [in Russian]
4. Shirokov V.A. Vybor nesteroidnykh protivovospalitel'nykh preparatov v lechenii bolevogo sindroma s pozitsii kardiovaskuliarnoi bezopasnosti. RMZh. 2015; 12: 716–9. [in Russian]
5. Loo C, Tan H, Teh H, Raymond A. Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J 2007; 48 (9): 834–9.
6. Strand V, Simon LS, Dougados M et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol 2011; 38 (12): 2625–34. doi: 10.3899/jrheum.110636. Epub 2011 Nov 1.
7. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8.
8. Juni P, Nartey L, Reichenbach S et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–29.
9. Kimmel SE, Berlin JA, Reilly M et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157–64.
10. Bresalier RS, Sandier RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102.
11. Karateev A.E., Iakhno N.N., Lazebnik L.B. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. M.: IMA-PRESS, 2009. [in Russian]
12. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiol 2000; 11: 382–7.
13. Garcia Rodriguez L, Varas-Lorenzo C, Maguire A et al. Non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in general population. Circulation 2004; 109: 3000–6.
14. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular eventswith naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105–11.
15. MacDonald T, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573–4.
16. Ray WA, Stein CM, Hall K et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118–23.
17. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of nonsteroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; Jan 11: 342: c7086. Doi: 10.1136/bmj.c7086.
18. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006; 296: 1633–44.
19. Wong D, Wang М, Cheng Y, Fitzgerald GA. Cardiovascular hazard and non-stertoidal anti-inflammatory drugs. Curr Opin Pharmacol 2005; 5: 204–10.
20. Chan CC, Reid CM, Aw TJ et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27 (12): 2332–41. Doi:10.1097/HJH.0b013e3283310dc9
21. Solomon D, Glynn R, Levin R, Avarn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099–4.
22. Vascular and upper gastrointestinal effects of non-steroidal anti-infl ammatory drugs: meta-analyses of individual participant data from randomised trials Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Lancet 2013; 382: 769–79.
23. Sharon Hertz. Cайт FDA.
24. Singh G, Graham D, Wang H et al. Concominant aspirin use reduces the risk of acute myocardial infarction in users of cyclooxygenase-2 selective and some nonselective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65 (Suppl. II): 61 (OP0024 abst.).
25. Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studie. Pharmacoepidemiol Drug Saf 2013; 22: 559–70. Doi: 10.1002/pds Published online 25 April 2013 in Wiley OnlineLibrary
26. Instruktsiia po meditsinskomu primeneniiu preparata Nalgezin. [in Russian]
27. Instruktsiia po meditsinskomu primeneniiu preparata Nalgezin forte. [in Russian]
Авторы
В.А.Широков
НПО «Клиника неврологии». 620014, Россия, Екатеринбург, ул. Московская, д. 12;
ФБУН Екатеринбургский медицинский научный центр профилактики и охраны здоровья рабочих промпредприятий Роспотребнадзора. 620075, Россия, Екатеринбург, ул. Попова, д. 30
vashirokov@gmail.com
НПО «Клиника неврологии». 620014, Россия, Екатеринбург, ул. Московская, д. 12;
ФБУН Екатеринбургский медицинский научный центр профилактики и охраны здоровья рабочих промпредприятий Роспотребнадзора. 620075, Россия, Екатеринбург, ул. Попова, д. 30
vashirokov@gmail.com
________________________________________________
V.A.Shirokov
Clinic of neurology. 620014, Russian Federation, Ekaterinburg, ul. Moskovskaia, d. 12;
Yekaterinburg Medical Research Center for Prophylaxis and Health Protection of Industrial Workers of Rospotrebnadzor. 620075, Russian Federation, Ekaterinburg, ul. Popova, d. 30
vashirokov@gmail.com
Clinic of neurology. 620014, Russian Federation, Ekaterinburg, ul. Moskovskaia, d. 12;
Yekaterinburg Medical Research Center for Prophylaxis and Health Protection of Industrial Workers of Rospotrebnadzor. 620075, Russian Federation, Ekaterinburg, ul. Popova, d. 30
vashirokov@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.